Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Trial details
- Registry ID
- NCT02004028
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as defactinib
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsNCT02004028 | VSTM | Phase 2 | Terminated | 2019-06-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |